Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9225875rdf:typepubmed:Citationlld:pubmed
pubmed-article:9225875lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:9225875lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:9225875lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:9225875lifeskim:mentionsumls-concept:C0449438lld:lifeskim
pubmed-article:9225875lifeskim:mentionsumls-concept:C0151449lld:lifeskim
pubmed-article:9225875lifeskim:mentionsumls-concept:C0008902lld:lifeskim
pubmed-article:9225875lifeskim:mentionsumls-concept:C0010362lld:lifeskim
pubmed-article:9225875lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:9225875lifeskim:mentionsumls-concept:C0392762lld:lifeskim
pubmed-article:9225875pubmed:issue3lld:pubmed
pubmed-article:9225875pubmed:dateCreated1997-8-14lld:pubmed
pubmed-article:9225875pubmed:abstractTextQuantitative and qualitative assessment of the clinical disease manifestations in 41 primary Sjögren's syndrome (pSS) patients was performed according to a new classification model. Frequencies of subgrouped disease manifestations were as follows: 1) surface exocrine disease: 100%, 2) internal organ exocrine disease: 63%, 3) monoclonal B lymphocyte disease: 5%, 4) inflammatory vascular disease: 71%, 5) non-inflammatory vascular disease: 59%, 6) mediator induced disease: 98%. Summary scores for severity of surface exocrine disease correlated to the summary scores of all other disease manifestations (p = 0.02), to the summary scores of internal organ exocrine disease (p = 0.003), and to the summary scores of mediator induced disease (p = 0.03). Blood leucocyte counts showed significant negative correlations to levels of plasma IgG, serum IgA-RF, IgM-RF, anti-SSA/SSB antibodies, IL-6, and IL-1Ra. We conclude that the model made detailed analysis of the clinical presentation of pSS possible, and thus may assist in elucidating important pathobiological aspect of the disease.lld:pubmed
pubmed-article:9225875pubmed:languageenglld:pubmed
pubmed-article:9225875pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9225875pubmed:citationSubsetIMlld:pubmed
pubmed-article:9225875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9225875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9225875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9225875pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9225875pubmed:statusMEDLINElld:pubmed
pubmed-article:9225875pubmed:issn0300-9742lld:pubmed
pubmed-article:9225875pubmed:authorpubmed-author:BendixenGGlld:pubmed
pubmed-article:9225875pubmed:authorpubmed-author:BendtzenKKlld:pubmed
pubmed-article:9225875pubmed:authorpubmed-author:AndersenVVlld:pubmed
pubmed-article:9225875pubmed:authorpubmed-author:WiigEElld:pubmed
pubmed-article:9225875pubmed:authorpubmed-author:PrauseJ UJUlld:pubmed
pubmed-article:9225875pubmed:authorpubmed-author:OxholmPPlld:pubmed
pubmed-article:9225875pubmed:authorpubmed-author:ThorpDDlld:pubmed
pubmed-article:9225875pubmed:authorpubmed-author:AsmussenKKlld:pubmed
pubmed-article:9225875pubmed:issnTypePrintlld:pubmed
pubmed-article:9225875pubmed:volume26lld:pubmed
pubmed-article:9225875pubmed:ownerNLMlld:pubmed
pubmed-article:9225875pubmed:authorsCompleteYlld:pubmed
pubmed-article:9225875pubmed:pagination197-205lld:pubmed
pubmed-article:9225875pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:meshHeadingpubmed-meshheading:9225875-...lld:pubmed
pubmed-article:9225875pubmed:year1997lld:pubmed
pubmed-article:9225875pubmed:articleTitleQuantitative assessment of clinical disease status in primary Sjögren's syndrome. A cross-sectional study using a new classification model.lld:pubmed
pubmed-article:9225875pubmed:affiliationDepartment of Medicine TA, Rigshospitalet, Copenhagen, Denmark.lld:pubmed
pubmed-article:9225875pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9225875pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed